Global Personalized Cell Therapies Market: By Cell Type (Hematopoietic Stem Cell, Skeletal Muscle Stem Cell, Mesenchymal Stem Cells, Lymphocytes, Others), By Application (Cardiovascular Disorders, Diabetes, Neurological Disorders, Cancer, Others), and Geography - Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

September 2017 | 215 pages | ID: G00A1499B54EN
Precision Business Insights (PBI)

Abstracts

Global Personalized Cell Therapies Market Report Description:

Personalized cell therapies market report gives comprehensive outlook on personalized cell therapies or cytotherapies across the globe with special emphasis on key regions such as North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa (MEA). This report on personalized cell therapies market gives historical, current, and future market sizes (US$ Mn) of cell type, application, and geographic regions. This report studies personalized cell therapies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the market report includes regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed personalized cell therapies market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the personalized cell therapies market report include suppliers, manufacturers, marketers, policy makers engaged in manufacturing and supply of personalized cell therapies.

Personalized Cell Therapies Market:

The personalized cell therapies market estimated to be valued US$ XX Mn in 2016 and expanding at a growth rate of 26.5%, and projected to reach US$ 18,000 Mn by 2023.

Adoptions of advanced technologies are expected to propel the personalized cell therapies market.

Research & Development is evolving, various cell types developed into treatments as novel cell therapies due to its potential applications. Bone marrow transplant or hematopoietic stem cell transplant widely used cell therapy due to treatment of blood cancer. Increased prevalence of cancer, rise in research and adoption of advanced technologies are expected attract the demand for personalized cell therapies market.

Rise in prevalence of chronic disorders and unmet needs in current treatment methods are expected to catapult the personalized cell therapies market.

Increasing prevalence of various disorders such as diabetes, cancer, auto immune disorders, neurovascular disorders are expected to create demand for personalized cell therapies market over the forecast period. Moreover, potential applications of cell therapies include treating autoimmune disease, cancers, infectious disease, urinary problems, spinal cord injuries, rebuilding damaged cartilage in joints, improving a weakened immune system, neurological disorders are expected to create lucrative opportunities for personalized cell therapies market.

North America has expected to account for major revenue share of global personalized cell therapies market

U.S. personalized cell therapies market is expected to grow at significant rate due to state-of-art healthcare infrastructure, increase in R&D, public and private funds for cellular therapies are expected to propel the market.

Asia pacific personalized cell therapies market is expanding at lucrative growth rate owing to increase in healthcare expenditure, rising awareness about novel cellular therapies in China and India.

Stringent regulations, limited awareness in low income countries are major restraints of the personalized cell therapies market.

COMPETITION ASSESSMENT

Key players’ profiles in the global personalized cell therapies market include:

• PCT Cell Therapy Services, LLC (U.S)
• U.S. Stem Cell, Inc. (U.S)
• Bellicum Pharmaceuticals, Inc. (U.S)
• Saneron CCEL Therapeutics, Inc. (U.S)
• StemGenex (U.S)
• Vericel Corporation.(U.S)
• Cytori Therapeutics Inc.(U.S.)
• MolMed S.p.A. (Italy)

Market players are focusing on robust invest in R&D, collaboration with government organizations, introduction of novel products are main strategies adopted by players in personalized cell therapies market. On August 19, 2016, The European Commission has granted conditional marketing authorization for Zalmoxis, patient specific adjunctive treatment in haplo identical hematopoietic stem cell transplantation for adults with hematological malignancies.

KEY FINDINGS OF THE REPORT:

• Personalized Cell Therapies market is expanding at 26.5% CAGR over 2017 to 2023 to reach market value of US$ 18,000 Mn by 2023
• Based on cell type, hematopoietic stem cell market is expected to dominate the revenue share over the forecast period.
• Based on region, North America is expected to account for major market share.
• Players focusing on expanding geographic presence to garner market opportunities in developing economies

KEY FEATURES OF THE REPORT:

• The report provides granular level information about the market size, regional market share, historic market (2012-2016) and forecast (2017-2023)
• The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
• The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
• The report tracks recent innovations, key developments and startup’s details that are actively working in the market
• The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
• The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market

DETAILED SEGMENTATION

By Cell Type

• Hematopoietic Stem Cell
• Skeletal Muscle Stem Cell
• Mesenchymal Stem Cells
• Lymphocytes
• Others

By Application

• Cardiovascular Disorders
• Diabetes
• Neurological Disorders
• Cancer
• Others

By Geography

• North America
• U.S
• Canada
• Europe
• Germany
• France
• U.K
• Italy
• Spain
• Russia
• Poland
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia & New Zealand
• ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
• South Korea
• Rest of Asia-Pacific
• Latin America
• Brazil
• Mexico
• Argentina
• Venezuela
• Rest of Latin America
• Middle East and Africa (MEA)
• Gulf Cooperation Council (GCC) Countries
• Israel
• South Africa

Rest of MEA

Contents

1. RESEARCH METHODOLOGY

1.1. Secondary and Primary research
  1.1.1. Secondary Sources
  1.1.2. Primary Sources
1.2. Market Revenue Estimation Methodology
1.3. Key Assumptions
1.4. Acronyms

2. SCOPE OF STUDY

2.1. Market Definition
2.2. Objective of the Research
2.3. Regions covered in the study

3. EXECUTIVE SUMMARY

4. GLOBAL PERSONALIZED CELL THERAPY MARKET DYNAMIC FACTORS

4.1. Drivers
  4.1.1. Economic Drivers
  4.1.2. Demand Side Drivers
  4.1.3. Supply Side Drivers
4.2. Restraints
4.3. Opportunities/Unmet Needs of the Market
4.4. Trends

5. UNIQUE FEATURES OF THE REPORT

5.1. Competition analysis
  5.1.1. Dash board of top players
  5.1.2. Financial Analysis
  5.1.3. Product & Services
  5.1.4. Key Developments
  5.1.5. Major Strategies
  5.1.6. SWOT Analysis
5.2. Technological advancements in personalized cell therapy Market
5.3. Recent investments in the industry
5.4. Regulatory landscape
  5.4.1. U.S.
  5.4.2. Europe
5.5. PESTLE analysis
5.6. Porter’s analysis

6. GLOBAL PERSONALIZED CELL THERAPY MARKET, BY CELL TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Hematopoietic Stem Cell
  6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.2. Skeletal Muscle Stem Cell
  6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.3. Mesenchymal Stem Cells
  6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.4. Lymphocytes
  6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
6.5. Others
  6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

7. GLOBAL PERSONALIZED CELL THERAPY MARKET FORECAST, BY APPLICATION, 2012 - 2016 AND FORECAST, 2017 – 2023

7.1. Cardiovascular Disorders
  7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.2. Diabetes
  7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.3. Neurological Disorders
  7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.4. Cancer
  7.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
7.5. Others
  7.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023(Revenue, USD Mn)
  7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

8. PERSONALIZED CELL THERAPY MARKET FORECAST, BY REGION ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America Personalized cell therapy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  8.1.1. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.1.1.1. Hematopoietic Stem Cell
    8.1.1.2. Skeletal Muscle Stem Cell
    8.1.1.3. Mesenchymal Stem Cell
    8.1.1.4. Lymphocytes
    8.1.1.5. Others
  8.1.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.1.2.1. Cardiovascular Disorders
    8.1.2.2. Diabetes
    8.1.2.3. Neurological Disorders
    8.1.2.4. Cancer
    8.1.2.5. Others
  8.1.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.1.3.1. U.S.
    8.1.3.2. Canada
8.2. Europe Personalized cell therapy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  8.2.1. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.2.1.1. Hematopoietic Stem Cell
    8.2.1.2. Skeletal Muscle Stem Cell
    8.2.1.3. Mesenchymal Stem Cell
    8.2.1.4. Lymphocytes
    8.2.1.5. Others
  8.2.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.2.2.1. Cardiovascular Disorders
    8.2.2.2. Diabetes
    8.2.2.3. Neurological Disorders
    8.2.2.4. Cancer
    8.2.2.5. Others
  8.2.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.2.3.1. Germany
    8.2.3.2. UK
    8.2.3.3. France
    8.2.3.4. Spain
    8.2.3.5. Italy
    8.2.3.6. Russia
    8.2.3.7. Poland 8.2.3.8. Rest of Europe
8.3. Asia-Pacific Personalized cell therapy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  8.3.1. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.3.1.1. Hematopoietic Stem Cell
    8.3.1.2. Skeletal Muscle Stem Cell
    8.3.1.3. Mesenchymal Stem Cell
    8.3.1.4. Lymphocytes
    8.3.1.5. Others
  8.3.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.3.2.1. Cardiovascular Disorders
    8.3.2.2. Diabetes
    8.3.2.3. Neurological Disorders
    8.3.2.4. Cancer
    8.3.2.5. Others
  8.3.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.3.3.1. Japan
    8.3.3.2. China
    8.3.3.3. India
    8.3.3.4. ASEAN
    8.3.3.5. Australia & New Zealand 8.3.3.6. Rest of Asia-Pacific
8.4. Latin America Personalized cell therapy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  8.4.1. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.4.1.1. Hematopoietic Stem Cell
    8.4.1.2. Skeletal Muscle Stem Cell
    8.4.1.3. Mesenchymal Stem Cell
    8.4.1.4. Lymphocytes
    8.4.1.5. Others
  8.4.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.4.2.1. Cardiovascular Disorders
    8.4.2.2. Diabetes
    8.4.2.3. Neurological Disorders
    8.4.2.4. Cancer
    8.4.2.5. Others
  8.4.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.4.3.1. Brazil
    8.4.3.2. Mexico
    8.4.3.3. Argentina
    8.4.3.4. Venezuela
    8.4.3.5. Rest of Latin America
8.5. Middle East & Africa (MEA) Personalized cell therapy Market Analysis, 2012 - 2016 and Forecast, 2017 - 2023
  8.5.1. Cell Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.5.1.1. Hematopoietic Stem Cell
    8.5.1.2. Skeletal Muscle Stem Cell
    8.5.1.3. Mesenchymal Stem Cell
    8.5.1.4. Lymphocytes
    8.5.1.5. Others
  8.5.2. Application Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.5.2.1. Cardiovascular Disorders
    8.5.2.2. Diabetes
    8.5.2.3. Neurological Disorders
    8.5.2.4. Cancer
    8.5.2.5. Others
  8.5.3. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) and Y-o-Y Growth (%)
    8.5.3.1. Gulf Cooperation Council (GCC) Countries
    8.5.3.2. Israel
    8.5.3.3. South Africa
    8.5.3.4. Rest of MEA

9. COMPETITION LANDSCAPE

9.1. Strategic Dashboard of Top Market Players
9.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
  9.2.1. PCT Cell Therapy Services, LLC (U.S)
  9.2.2. U.S. Stem Cell, Inc. (U.S)
  9.2.3. Bellicum Pharmaceuticals, Inc. (U.S)
  9.2.4. Saneron CCEL Therapeutics, Inc. (U.S)
  9.2.5. StemGenex (U.S)
  9.2.6. Vericel Corporation.(U.S)
  9.2.7. Cytori Therapeutics Inc.(U.S.)
  9.2.8. MolMed S.p.A. (Italy)